CSPG4-specific antibodies, and engineered chimeric antigen receptor (CAR) lymphocyte therapies, have previously been shown to significantly reduce lung metastases and tumor recurrence in mouse models of melanoma3,42–48. This evidence concerns the gene CSPG4 and neoplasm.